Day: March 25, 2021

Jordan Babineaux, Entrepreneur, Sportscaster, Author, and Former Professional Football Player to be Spokesperson for Bank on 100 Million Campaign

Written by Customer Service on March 25, 2021. Posted in Public Companies.

Designed to encourage the private sector to evaluate employees and consumers with records more fairly BALTIMORE, MD, March 25, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Global Boatworks Holdings, Inc. (OTC: GBBT), (“Global” or “the Company”) the holding company of R3 Score an innovative provider of better-contextualized data to businesses for the 1-in-3 Americans living with a criminal record, and consumers with thin credit files, today announced that Jordan Babineaux, entrepreneur, author, sportscaster and former professional football player, has signed on to be a public spokesperson for the Bank on 100 Million campaign. Jordan Babineaux has demonstrated his commitment to criminal justice through his own efforts as a fair chance employer in his company Assure Ride. As a business owner, he understands...

Allied Corp Increases Intellectual Property Protection by Filing Trademark for Pharma Product PSILONEX

Written by Customer Service on March 25, 2021. Posted in Public Companies.

KELOWNA, British Columbia, March 25, 2021 (GLOBE NEWSWIRE) — Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce that it has successfully filed for trademark protection for its pharmaceutical product “PSILONEX.” PSILONEX is a proprietary formulation prescribed within a treatment path that involves both a pharmaceutical psilocybin-based formulation, followed by a daily cannabinoid maintenance period. PSILONEX is intended to be prescribed by a physician as “PSILONEX Rx,” followed by the cannabinoid daily therapy that can be purchased by the consumer in regions where it is legal to do so as “PSILONEX Daily,” Both of these products are currently being researched, developed...

Sbanken ASA: Tap Issue ISIN NO0010920762

Written by Customer Service on March 25, 2021. Posted in Public Companies.

Tap Issue Sbanken ASA 21/24 FRN, ISIN NO0010920762, amount NOK 200.000.000,-. Outstanding amount NOK 500.000.000,-. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Sbanken ASA: Utvidelse av ISIN NO0010920762

Written by Customer Service on March 25, 2021. Posted in Public Companies.

Utvidelse av Sbanken ASA 21/24 FRN, ISIN NO0010920762, beløp NOK 200.000.000,-. Nytt utestående volum NOK 500.000.000,-. Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

GTX Corp Begins Exporting Hearing Related Products and Rapid Antigen and Antibody Test Kits to the UK

Written by Customer Service on March 25, 2021. Posted in Public Companies.

LOS ANGELES, CALIFORNIA, March 25, 2021 (GLOBE NEWSWIRE) — GTX Corp (OTC: GTXO) (“GTX” or the “Company”), a pioneer in the field of wearable GPS human and asset tracking systems and a supplier of Health and Safety personal protective medical equipment “PPE”, announced today it will start exporting its Rapid Diagnostic Test-Kits for Antigens and Antibodies, along with hearing related products to distributors in the United Kingdom. GTX has built a network of partners that have been distributing many of its products through B2B Healthcare and Telehealth providers across Europe which supply, install and support Electronic Assistive Technology products and systems to the National Health Services and enabled care and support markets. Phil Iles, Possum Sales Manager for UK & EIRE, stated “Since we originally launched the GPS SmartSoles...

Engine Bearings Market Size 2021 | Worth USD 5.28 Billion at 12.6% CAGR by 2027; Rising Demand for Light-weight Automotive Components to Favor Growth: Fortune Business Insights™

Written by Customer Service on March 25, 2021. Posted in Mergers And Acquisitions.

Pune, India, March 25, 2021 (GLOBE NEWSWIRE) — According to the report, Engine Bearings Market size is projected to reach USD 5.28 Billion value by 2027, exhibiting a CAGR of 12.6%. This is ascribable to the increasing sales of automotive leading to the massive production rate of vehicles by the manufacturers across the globe. An engine bearing is a component that is extensively adopted in an automotive to reduce friction between the moving parts. They facilitate the desired movement of the engine without experiencing a loss in power. Considered to be one of the revolutionary human innovations amongst machines, they are capable of carrying heavy-duty loads and aid in the optimum functioning of the crankshaft. The engine bearing is located in the crankcase and has an average lifespan of about 1, 36,000 to over 1, 60,000...

EgnsINVEST Ejendomme Tyskland A/S – Resultat for 2020 – 37,1 mio. kr.

Written by Customer Service on March 25, 2021. Posted in Public Companies.

Den 25. marts 2021 Uddrag fra ledelsesberetningenEBVAT på 23,4 mio. kr. for 2020 Værdireguleringer på 13,8 mio. kr. i 2020 Egenkapitalforrentningen før dagsværdiregulering og skat er 3,8% i 2020 Bestyrelsen indstiller til, at der udbetales udbytte på 1,00 kr. pr. aktieEgnsINVEST Ejendomme Tyskland A/S har realiseret et resultat før skat i 2020 på i alt 37,1 mio. kr. på koncernniveau, hvilket ledelsen betragter som tilfredsstillende. Af årets resultat udgør værdiregulering af investeringsejendommene 13,8 mio. kr. Driftsresultatet (EBVAT) er dermed på 23,4 mio. kr., hvilket ligger inden for det forventede interval på mellem 22,5-24,0 mio. kr., som tidligere er blevet meldt ud. I starten af 2020 vedtog Berlins senat en ny lov, som blandt andet fastfryser lejen i boliger, så lejen ikke kan stige i fem år, og som fastlægger øvre grænser...

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Written by Customer Service on March 25, 2021. Posted in Earnings Releases And Operating Results.

BURLINGAME, Calif., March 25, 2021 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2020. “In 2020, we made considerable progress expanding our technology platform to address COVID-19 and other infectious diseases. As a result, we have extended our product development strategy with the initiation of a Phase 3 study of CPI-006 for COVID-19. In a recently completed Phase 1 study, CPI-006 induced robust and prolonged anti-SARS-CoV-2 antibody responses,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “During the year we also co-founded Angel Pharmaceuticals, a new biopharma company in China that is positioned to develop...

II-VI Incorporated to Acquire Coherent, Creating Global Leader in Photonic Solutions, Compound Semiconductors, and Laser Technology and Systems

Written by Customer Service on March 25, 2021. Posted in Mergers And Acquisitions.

$250 million in annual cost synergies expected to be realized within 36 months of closingAnticipated to be accretive to Non-GAAP EPS in second year following closing PITTSBURGH, March 25, 2021 (GLOBE NEWSWIRE) — II-VI Incorporated (Nasdaq: IIVI), a global leader in engineered materials and optoelectronic components, today announced that it is entering into a definitive agreement with Coherent, Inc. (Nasdaq: COHR), one of the world’s leading providers of lasers, laser-based technologies and laser-based system solutions, under which II-VI will acquire all outstanding Coherent shares in a cash and stock transaction. Under the terms of the transaction, Coherent shareholders will receive $220.00 in cash and 0.91 of a share of II-VI common stock for each Coherent share. “We are pleased to have reached an agreement with Coherent...

Étude clinique : la prothèse totale de genou réalisée avec la technologie Conformis sur un patient donné est plus rentable qu’avec les implants prêts à l’emploi les plus utilisés

Written by Customer Service on March 25, 2021. Posted in Public Companies.

BILLERICA, Mass., 25 mars 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ : CFMS) a annoncé aujourd’hui les résultats d’un examen rétrospectif indépendant de données hospitalières concluant que la technologie de prothèse totale du genou Conformis iTotal® se révèle plus rentable que les traditionnels implants prêts à l’emploi de grande marque. Plus important encore, cette étude a été réalisée de manière indépendante sans parrainage ni financement de la part de Conformis. Le nouveau compte-rendu a été présenté par ses auteurs lors de la réunion annuelle de l’Orthopaedic Research Society en 2021 (réunion annuelle ORS 2021), qui s’est tenue en février de cette année. L’arthroplastie totale conçue sur mesure est rentable par rapport à un implant standard, Navin Fernando MD, Ann chancelier CCRC, Paul...

Day: March 25, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals